PT1244650E - Derivados arilaminas e sua aplicacao como agentes anti-telomerase - Google Patents

Derivados arilaminas e sua aplicacao como agentes anti-telomerase

Info

Publication number
PT1244650E
PT1244650E PT00985339T PT00985339T PT1244650E PT 1244650 E PT1244650 E PT 1244650E PT 00985339 T PT00985339 T PT 00985339T PT 00985339 T PT00985339 T PT 00985339T PT 1244650 E PT1244650 E PT 1244650E
Authority
PT
Portugal
Prior art keywords
arillamine
derivatives
application
agents
telomerase
Prior art date
Application number
PT00985339T
Other languages
English (en)
Inventor
Patrick Mailliet
Jean-Francois Riou
Jean-Louis Mergny
Abdelazize Laoui
Francois Lavelle
Odile Petitgenet
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9915031A external-priority patent/FR2801588B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PT1244650E publication Critical patent/PT1244650E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • C07D215/46Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40Nitrogen atoms
    • C07D251/54Three nitrogen atoms
    • C07D251/70Other substituted melamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
PT00985339T 1999-11-29 2000-11-27 Derivados arilaminas e sua aplicacao como agentes anti-telomerase PT1244650E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9915031A FR2801588B1 (fr) 1999-11-29 1999-11-29 Derives chimiques et leur application comme agent antitelomerase
FR0010561 2000-08-11

Publications (1)

Publication Number Publication Date
PT1244650E true PT1244650E (pt) 2003-11-28

Family

ID=26212577

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00985339T PT1244650E (pt) 1999-11-29 2000-11-27 Derivados arilaminas e sua aplicacao como agentes anti-telomerase

Country Status (27)

Country Link
EP (1) EP1244650B1 (pt)
JP (1) JP2003515604A (pt)
KR (1) KR20020058043A (pt)
CN (1) CN1402722A (pt)
AT (1) ATE243692T1 (pt)
AU (1) AU2179001A (pt)
BG (1) BG106753A (pt)
BR (1) BR0015992A (pt)
CA (1) CA2392507A1 (pt)
CO (1) CO5251431A1 (pt)
CZ (1) CZ20021849A3 (pt)
DE (1) DE60003583T2 (pt)
DK (1) DK1244650T3 (pt)
EA (1) EA200200616A1 (pt)
EE (1) EE200200263A (pt)
ES (1) ES2202206T3 (pt)
HU (1) HUP0204429A2 (pt)
IL (1) IL149402A0 (pt)
MX (1) MXPA02005276A (pt)
NO (1) NO20022528L (pt)
PE (1) PE20010912A1 (pt)
PL (1) PL355667A1 (pt)
PT (1) PT1244650E (pt)
SK (1) SK7402002A3 (pt)
UY (1) UY26456A1 (pt)
WO (1) WO2001040218A1 (pt)
YU (1) YU38102A (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE396978T1 (de) 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
JP2003520855A (ja) * 2000-01-28 2003-07-08 アストラゼネカ アクチボラグ 化学的化合物
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
WO2002012194A1 (fr) * 2000-08-08 2002-02-14 Aventis Pharma S.A. Derives de phenanthridine et leur application comme agents antitelomerases
US7105530B2 (en) * 2000-12-21 2006-09-12 Smithkline Beecham Corporation Pyrimidineamines as angiogenesis modulators
FR2821355A1 (fr) * 2001-02-23 2002-08-30 Aventis Pharma Sa Derives chimiques et leur application comme agent antitelomerase
US6887873B2 (en) 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
FR2822468B1 (fr) * 2001-03-23 2008-06-20 Aventis Pharma Sa Derives chimiques et leur application comme agent anti-telomerase
CO5380035A1 (es) * 2001-03-23 2004-03-31 Aventis Pharma Sa Derivados quimicos y su aplicacion como agente antitelomerasa
EP1401833A2 (fr) 2001-05-28 2004-03-31 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase
US7115617B2 (en) * 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7169785B2 (en) 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7132423B2 (en) 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
JP2005519876A (ja) 2001-11-27 2005-07-07 メルク エンド カムパニー インコーポレーテッド 2−アミノキノリン化合物
BR0314195A (pt) * 2002-09-10 2005-07-26 Pharmacia Italia Spa Derivados de piridina substituìda como agentes antitumorais
AU2003275726A1 (en) * 2002-10-24 2004-05-13 Chong Kun Dang Pharmaceutical Corp. 2 - substituted heterocyclic compounds and antitumor composition comprising the same
FR2850970B1 (fr) * 2003-02-07 2006-07-07 Aventis Pharma Sa Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
EP1691812A4 (en) * 2003-11-20 2010-01-13 Childrens Hosp Medical Center GTPASE INHIBITORS AND METHOD OF USE
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
WO2007049057A2 (en) * 2005-10-28 2007-05-03 Iti Scotland Limited Novel fluorescent dyes and uses thereof
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
KR100761869B1 (ko) * 2006-07-07 2007-10-04 김현기 트리아진 유도체 화합물 및 이를 포함하는 암 치료용조성물
EP2046763A2 (en) * 2006-07-31 2009-04-15 Praecis Pharmaceuticals Incorporated Aurora kinase inhibitors from an encoded small molecule library
JP5325517B2 (ja) * 2007-10-12 2013-10-23 住友化学株式会社 ジベンゾオキセピン化合物の精製方法
JP2009102249A (ja) * 2007-10-22 2009-05-14 Sumitomo Chemical Co Ltd ジベンゾオキセピン化合物の結晶の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206768D0 (en) * 1992-03-27 1992-05-13 Jarman Michael New compounds for use in the treatment of cancer
US5770613A (en) * 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
JPH1160573A (ja) * 1997-08-22 1999-03-02 Nippon Kayaku Co Ltd トリアジン誘導体及びテロメラーゼ阻害剤
ATE244241T1 (de) * 1998-02-04 2003-07-15 Univ Texas Hemmung der menschlichen telomerase durch g- quadruplex interaktionverbindung
DE19812879A1 (de) * 1998-03-24 1999-09-30 Bayer Ag Substituierte 2,4-Diamino-1,3,5-triazine

Also Published As

Publication number Publication date
AU2179001A (en) 2001-06-12
EA200200616A1 (ru) 2002-10-31
PL355667A1 (en) 2004-05-04
CZ20021849A3 (cs) 2002-08-14
DE60003583D1 (de) 2003-07-31
EP1244650B1 (fr) 2003-06-25
CO5251431A1 (es) 2003-02-28
BR0015992A (pt) 2002-08-06
HUP0204429A2 (hu) 2003-04-28
NO20022528D0 (no) 2002-05-28
SK7402002A3 (en) 2002-11-06
CA2392507A1 (fr) 2001-06-07
WO2001040218A1 (fr) 2001-06-07
EE200200263A (et) 2003-06-16
CN1402722A (zh) 2003-03-12
KR20020058043A (ko) 2002-07-12
MXPA02005276A (es) 2002-11-07
DE60003583T2 (de) 2004-05-13
UY26456A1 (es) 2001-06-29
ATE243692T1 (de) 2003-07-15
IL149402A0 (en) 2002-11-10
YU38102A (sh) 2004-12-31
NO20022528L (no) 2002-05-28
JP2003515604A (ja) 2003-05-07
ES2202206T3 (es) 2004-04-01
DK1244650T3 (da) 2003-10-20
BG106753A (bg) 2003-02-28
PE20010912A1 (es) 2001-09-01
EP1244650A1 (fr) 2002-10-02

Similar Documents

Publication Publication Date Title
PT1244650E (pt) Derivados arilaminas e sua aplicacao como agentes anti-telomerase
ATE461217T1 (de) Glp-1-verbindungen
ATE231872T1 (de) Thiazolopyrimidinderivate
DE69907977D1 (de) Pyrrolobenzodiazepine
BRPI0411617A (pt) derivados de pirimidina como ligantes de receptores de canabinóides
PT797439E (pt) Utilizacao de pramipexote como agente neuroprotector
CY1110721T1 (el) Χρηση glp-2 σε συνδυασμο με αλλο θεραπευτικο παραγοντα σε οστικες παθησεις
DE60112974D1 (en) Carbolinderivate
SG145695A1 (en) Pyridyl derivatives and their use as therapeutic agents
SG145700A1 (en) Pyridyl derivatives and their use as therapeutic agents
WO2002096903A3 (fr) Derives chimiques et leur application comme agent antitelomerase
BR0208338A (pt) Derivados de piridina
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
CY2008007I2 (el) Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου
PT1235558E (pt) Agentes terapeuticos
ATE346067T1 (de) Carbolinderivate
SE9904377D0 (sv) Pharmaceutical combinations
HK1076812A1 (en) Cyanoguanidine prodrugs
MY130957A (en) Triazine derivatives and their application as antitelomerase agents
ATE306283T1 (de) Biotin-derivate und ihre konjugaten mit chelatierungsmitteln
PT1224181E (pt) Pirrois substituidos uteis como agentes antiproliferativos para o tratamento do cancro
ATE250340T1 (de) 7-methylthiooxomethyl- und 7- methylthiodioxomethyl-paclitaxele
MXPA04005226A (es) 1,3-diarilprop-2-en-1-onas, composiciones que las contienen y su utilizacion.
PT1235809E (pt) 1,2,3,4,5,6-hexa-hidro-2,6-metano-3-benzazocinas substituidas e sua utilizacao como medicamentos
DE10157913B4 (de) Therapietisch